Aug 06, 2025 • Benzinga
NEUTRAL
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference - Merus ( NASDAQ:MRUS )
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Merus N.V.
Aug 06, 2025 • GlobeNewswire
NEUTRAL
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Merus N.V. ( Nasdaq: MRUS ) , an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates ( Biclonics®, Triclonics® and ADClonics® ) , today announced that Bill ...
Jul 11, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success
Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.
Jun 04, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Merus N.V. Announces Pricing of Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 ( GLOBE NEWSWIRE ) -- Merus N.V. ( Nasdaq: MRUS ) ( "Merus", the "Company," "we" and "our" ) , an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates ( Biclonics®, Triclonics® and ...
May 27, 2025 • Benzinga
SOMEWHAT-BULLISH
Merus to Present at Upcoming Investor Conferences - Merus ( NASDAQ:MRUS )
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 27, 2025 ( GLOBE NEWSWIRE ) -- Merus N.V.
May 23, 2025 • Benzinga
SOMEWHAT-BULLISH
Merus Stock Surges Over 35% On Strong Phase 2 Cancer Trial Results: What's Going On? - Merus ( NASDAQ:MRUS )
Merus shares surged over 35% after reporting a 63% response rate and 79% 12-month survival in a phase 2 trial. Analysts raised price targets on optimism the data could support accelerated approval and position the drug as a new standard of care.